Safety of omalizumab in asthma

Bibliography

• Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med 2006;355(12):1281-2
   PubMed Web of Science ®Google Scholar
• Easthope S, Jarvis B. Omalizumab. Drugs 2001;61(2):253-60, discussion 261
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson SJ, Kraft M, Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170(6):583-93
   PubMed Web of Science ®Google Scholar
• Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131(1):46-52
   PubMed Web of Science ®Google Scholar
• Beck LA, Marcotte GV, MacGlashan D, Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004;114(3):527-30
   PubMed Web of Science ®Google Scholar
• MacGlashan DW Jr, Bochner BS, Adelman DC, Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158(3):1438-45
   PubMed Web of Science ®Google Scholar
• Silkoff PE, Romero FA, Gupta N, Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 2004;113(4):e308-12
   PubMed Web of Science ®Google Scholar
• Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94-138
   PubMed Web of Science ®Google Scholar
• Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99(2):190-3
   PubMed Web of Science ®Google Scholar
• Casale TB, Condemi J, LaForce C, Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286(23):2956-67
   PubMed Web of Science ®Google Scholar
• Sheinkopf LE, Rafi AW, Do LT, Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29(5):530-7
   PubMed Web of Science ®Google Scholar
• Rafi A, Do LT, Katz R, Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 2010;31(1):76-83
   PubMed Web of Science ®Google Scholar
• Klunker S, Saggar LR, Seyfert-Margolis V, Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007;120(3):688-95
   PubMed Web of Science ®Google Scholar
• Long AA, Fish JE, Rahmaoui A, Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009;103(3):212-19
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-90
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254-61
   PubMed Web of Science ®Google Scholar
• Corren J, Casale T, Deniz Y, Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111(1):87-90
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91(2):154-9
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59(7):709-17
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Casale T, Townley R, Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91(2):160-7
   PubMed Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109(2):274-80
   PubMed Web of Science ®Google Scholar
• Casale TB, Busse WW, Kline JN, Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117(1):134-40
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39(6):788-97
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab versus placebo as add on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011;139(1):28-35
   PubMed Web of Science ®Google Scholar
• Vesterinen E, Pukkala E, Timonen T, Cancer incidence among 78,000 asthmatic patients. Int J Epidemiol 1993;22(6):976-82
   PubMed Web of Science ®Google Scholar
• Reynolds P, Kaplan GA. Asthma and cancer. Am J Epidemiol 1987;125(3):539-40
   PubMed Web of Science ®Google Scholar
• Kallen B, Gunnarskog J, Conradson TB. Cancer risk in asthmatic subjects selected from hospital discharge registry. Eur Respir J 1993;6(5):694-7
   PubMed Web of Science ®Google Scholar
• Limb SL, Starke PR, Lee CE, Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007;120(6):1378-81
   PubMed Web of Science ®Google Scholar
• Cruz AA, Lima F, Sarinho E, Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007;37(2):197-207
   PubMed Web of Science ®Google Scholar
• Omalizumab: cardiac adverse effects. Prescrire Int 2010;19(106):75
   Google Scholar
• Ruppert AM, Averous G, Stanciu D, Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 2008;121(1):253-4
   PubMed Web of Science ®Google Scholar
• D'Cruz DP, Barnes NC, Lockwood CM. Difficult asthma or Churg-Strauss syndrome? BMJ 1999;318(7182):475-6
   PubMed Web of Science ®Google Scholar
• Bargagli E, Madioni C, Olivieri C, Churg-Strauss vasculitis in a patient treated with omalizumab. J Asthma 2008;45(2):115-16
   PubMed Web of Science ®Google Scholar
• Buhl R, Soler M, Matz J, Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20(1):73-8
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34(4):632-8
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59(7):701-8
   PubMed Web of Science ®Google Scholar
• Adelroth E, Rak S, Haahtela T, Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106(2):253-9
   PubMed Web of Science ®Google Scholar